GOAL IS TO ESTABLISH AN AMERICAN COMPANY TO SUPPORT THE HEALTH COMMUNITY
WITH THERAPEUTICS, DIAGNOSTICS AND LIFE STYLE DRUGS (NATURAL INTACT
MOLECULES USING MODERN SCIENCE)
*We are focused to support our innovation and discoveries by selling diagnostic kits and
life style drugs
* At this point our next stage which is clinical trials for Hybrid Paclitaxel and marketing of
life style drugs require more funds
STRENGTH AT PRESENT
 INNOVATIVE SCIENCE AND SCIENTISTS
 DIAGNOSTICS TEST KITS TO GENERATE SOME REVENUE
 LIEF STYLE DRUGS FROM NATURAL MOLECULES READY
FOR MARKETING IN FACT ALREADY IN MARKET AND HAVE
STARTED GENERATING SOME REVENUE TO PAY OUR RENT.
GREAT ACCEPTABILITY WITH 100% +VE FEED BACK
 A PATENTED DISCOVERY TO DEVELOP HYBRID DRUGS
 WE FOCUS ON PACLITAXEL ( NEED NOT TO DESCRIBE A
GOLDEN BULLET FOR CANCER SO FAR) IS READY FOR
CLINICAL TRILAS. I WILL DISCUSS MORE DETAILS IN NEXT
SLIDES
MewTaxel
DISCOVERY OF HYBRID DRUGS
Potent, Safe and Patented
A MOLECULE= NON SOLUBLE IN WATER
B MOLECULE= NON SOLUBLE IN WATER
C MOLECULE = SOLUBLE IN WATER
A+B = NON SOLUBLE IN WATER
A+C = NON SOLUBLE IN WATER
A+B+C = IS SOLUBLE IN WATER WHICH IS AN INNOVATION
OR DISCOVERY AND IS THE NEED OF THE DRUG. THE
DISCOVERY DOES NOT ALTER ANY OF THE MOLECULE
PARTNER IN THIS HYBRID.
PACLITAXEL HYBRID
MewTaxel
HYBRID CPT251(MewTaxel)
A NEW TREATMENT FOR CANCER
SAFE AND MORE EFFECTIVE CHEMOTHERAPY
Dr.Mewa Singh
609-902-7128
mewasinghsandhu@hotmail.com
www.nanosgroup.com / Meda Biotech , USA
MewTaxel
RATIONAL
 $5B MARKET FREE FROM PATENT
 CAPTURE THE MARKET WITH NEW PATENT PROTECTION
 EITHER BY IMPROVEMENT
 EITHER BY CHANGING THE MOLECULE
 EITHER BY CONJUGATION OR HYBRIDIZATION
 DECREASE TOXICITY
 INCREASE EFFICACY
 OUR TECHNOLOGY IS SIMPLE (WITHOUT ANY POLYMER
CONJUGATION)- HYBRID. MANUFACTURING COST IS LOW
 COMPANIES HAD AND HAVE INVESTED 100M $ ON THIS. WE
JUST GOT THE SAME IN JUST LITTLE OVER 1M$! OFF COURSE
WE ARE NOT CALCULATING OUR TIME INVESTMENT.
MewTaxel
PROBLEM
 SOLUBILITY
 TOXICITY (The castor-oil carrier is suspected as the
culprit behind the misery which includes nausea,
vomiting, joint pain, appetite loss, brittle hair and
tingling sensations in hands and feet (neuropathy).
 DRUG RESISTANCE
 MANUFACTURING AND ADMINISTING COST AT CLINIC
 PATENT PROTECTION (Expired)
 THREAT OF GENERIC TO EXISTING ESTABLISHED
MARKET
 HIGH PRODUCTION AND ADMINISTRATION ON SITE
COST
MewTaxel
IMPROVED AND NEW
MewTaxel

WATER SOLUBLE

HYBRID, DOUBLE EDGE FORMULATION

LESS TOXIC

HIGH POTENCY

LOW MANUFACTURING AND ADMINISTRATION COST AT CLINIC

NO CHANGE IN INTEGRITY OF THE MOLECULES

PATENT FILED FOR NEW INVENTION FOR HYBRID.

NO CASTOR OIL, NO ALCOHOL, NO DETERGENT, NO PROTEIN, NO CHEMISTRY CHANGE ON
TOP OF THAT IT IS MORE POTENT, LESS TOXIC AND LESS MANUFACTURING COST.

NO COMPLEX CONJUGATION STEP

LOW MANUFACTURING COST AND SIMPLE AT DRs. SITE
MewTaxel
MewTaxel
PROGRESS
 PROOF OF CONCEPT -------------ESTABLISHED
 R & D---------------------------------ESTABLISHED
 PILOT SCALE MANUFACTURING---ESTABLISHED
 IN-VITRO STUDY-------------------PRELIMINARY
TESTING ESTABLISHED
 ANIMAL STUDIES-------------- ON-GOING
MewTaxel
FUNDS
 $1M INVESTED
 $3M NEEDED ( ANALYTICAL TOOL, CGMP
MANUFACTURING, PRE-CLINICAL, IND, CLINICAL)
 $1M WILL BE INVESTED FOR MANUFACTURING
AND MARKETING OF OUR DIAGNOSTIC KITS AND
LIFE STYLE DRUGS
 $2M WILL BE FOR cGMP, QC, PRECLINICALS AND
PHASE-I CLINICALS
MewTaxel
MILESTONES
 Scale Manufacturing
(2012)
 Animal efficacy: Drug Interactions
(2013)
 IND
 Phase I
 Phase II
 License submission
(2014)
(2015)
(2016-17)
(2017-18)
MewTaxel
POTENCY
10000000
8000000
6000000
4000000
2000000
0
Plate 1
1
0.5
0.25
0.125
0.0625
0.03125
0.015625
Live Cells
MewTaxel is Potent at 1.1 nM ( ic50 is 30nM)
MewTaxel is potent at 5nm ( ic50 is >60nM)
Much lower than taxol
Concentration (µg)
P average
MewTaxel
SAFE AND POTENT THE MEWTAXEL
Paclitaxel in water
MewTaxel in water
Solubility
NO CASTOR OIL,
NO ALCOHOL,
NO DETERGENT,
NO PROTEIN,
NO CHEMISTRY CHANGE
ON TOP OF THAT
IT IS MORE POTENT,
LESS TOXIC AND
COST EFFECTIVE.
Act on multiple site
MewTaxel
SYNERGISTIC/POTENTIATING
INNOVATIVE:
TAxolMew suppresses production of
proteins needed for uncontrolled growth
and proliferation, inflammation and inhibition
of PGE-2. TAxolMew inactivates NF-kappa B,
genes involved in cell proliferation, such as COX2, cyclin D1, and c-myc.
TaxolMew also helps to restore normal
programmed cell death.
In a study, taxol induced NF-kappa B activation
led to cell immortality, reducing the drug's
ability to kill cancer cells. Drug resistance is a
huge problem. But TAxolMew can help to make
chemotherapeutic agents more effective.
Hybrid Partner
Arrested stem cell development. TaxolMew
inhibits growth and renewal of so-called cancer stem
cells, aberrant cells now believed to be at the root of
many cancers, including breast cancer.
TaxolMew inhibited taxol's inflammatory
response by blocking nuclear factor-kappa B (NF-kappa
B) which regulates inflammation, cell proliferation, and
apoptosis (cell death).
Mitotic arrest-Taxol
MewTaxel
LAST BUSINESS DEAL ( VALUE)
 Now that Celgene has wrapped up its $3 billion-plus buyout of
Abraxis BioScience, analysts are cheering. That wasn't necessarily
the case in June, when the companies announced their deal--and
investors responded by selling off their stock, sending the price
plummeting to $48. But as Investor's Business Daily reports,
Celgene shares are now trading at near $60, and observers think
the combo will eventually transform the company into a
"biopharmaceutical giant."
Read more: Abraxis deal done, Celgene eyes cancer franchise FiercePharma http://www.fiercepharma.com/story/abaxis-dealdone-celgene-eyes-cancer-franchise/2010-10-25#ixzz1ibPApSSD
We took even albumin out and made it soluble Hybrid
MewTaxel should has a better deal
MARKET OVERVIEW
 EXISTING MARKET IS $5BILLION
 SINCE IT IS IN CLINICAL TRIAL WITH MANY
COMBINATION WITH BIOLOGICS AND MANY OTHER
CANCER TREATMENTS, IT WILL GROW IN FUTURE
 WE ARE VERY DIFFERENT THAN ANY OTHER
FORMULATION , SO AFTER CLINICAL, WE HAVE A
BETTER POSITION IN MARKET
 NOT A ME-TOO CONCEPT BUT DISTINGUISH
YOURSELF AWAY FROM COMPETITION
 Abbott Laboratories, Aphios Corporation, Angiotech, Inc., British
Technology Group, Cell Therapeutics, Inc., Dabur India Ltd.
Enzon, Inc., F.H. Faulding & Co. Ltd., Guilford Pharmaceuticals,
Inc., Hauser, Inc., IVAX Corp., LDS Technologies, Inc., MacroMed,
Inc., Matrix Pharmaceuticals, Inc., Mylan Laboratories, Inc.
NaPro BioTherapeutics, Inc., Natural Pharmaceuticals, Inc.,
Natland International Corporation
NeoPharm, Inc., Novopharm Biotech, Inc., Novopharm Ltd., N.V.
Boehringer-Ingelheim SA
Pharmacia & Upjohn Co., Phytogen Life Sciences, Inc., Phyton
Catalytica, Protarga, Inc., Samyang Genex Corp., Schein
Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc., STS Particles, Inc./Medisperse
Supergen, Inc., Taxalog, Inc., Teva Pharmaceutical Industries, Ltd.
The Liposome Company, VivoRx Pharmaceuticals, Inc.
NON OF THEM ARE WITH
HYBRID TECHNOLOGY
 BEST IS TO JOIN WITH BIG PHARMA
 BUT IF FUNDED OR GENERATE ENOUGH
REVENUE FROM OUR OTHER PRODUCTS TO
SUPPORT ALL CLINICAL TRIALS, A BETTER VALUE
CAN BE BUILD UP FOR THE COMPANY
MANAGEMENT OVERVIEW
 Mewa Singh. PhD : Inventor, investor and COO. More
than 20 years of experience in Diagnostics, Vaccine ,
therapeutics. He has delivered more than 30
products. All are in the market. He has experience to
take the product from concept to market.
 Maninder Sandhu, MA Economics: She has been
managing the financial , accounts and day to day
management of the company here in USA and India.
 Jagjit Saluja, BSc : Creating sale in India for
diagnostic kits and catering day to day material for
company
Arthur R. Cooper
Arthur Cooper serves as CEO of the LSU System Research and Technology
Foundation with a focus on helping Louisiana Universities commercialize
their technology. He also is the Executive Director of the Louisiana Emerging
Technology Center and is responsible for operation of the Baton Rouge Life
Science incubator. He previously served as director of Business, Retention
and Assistance Services for the Louisiana Department of Economic
Development and as such he worked closely with the Small Business
Development Centers, local chambers of commerce, micro enterprise
development centers, and local economic developers. Arthur is a Baton
Rouge native with 16 years experience in the practice of law, with extensive
work in intellectual property issues. He was a design engineer, CEO of a
startup biotech food company and a managing partner of a law firm. He has
a B.S. in Electrical Engineering from Louisiana State University and a J.D.
(Juris Doctor) from Louisiana State University Law Center.
K. Gus Kousoulas, PhD :
Affiliate
Member, Stanley S. Scott Cancer Center, LSUHSC,
New Orleans Director, Division of Biotechnology &
Molecular Medicine (BIOMMED)
Director, LSU-Tulane Center for Experimental
Infectious Disease Research School of Vet. Med. Bldg.
Room 3110 Skip Bertman Drive
Baton Rouge, LA 70803 Phone: 225-578-9682 Fax:
225-578-9655 email: vtgusk@lsu.edu
 Dr. Anil Kumar Chawla
Scientist
Quality, Safety and Standards
Department of Immunization Vaccines and
Biologicals
World Health Organization
Geneva, Switzerland
Tel. + 41 22 791 5566
Fax. + 41 22 791 4384
email. chawlaa@who.int
 Dr. Manjit Singh MS ( Therapeutic Oncology)
Clinical trial
Professor at Medical College, Amritsar, India
Need to have Regulatory and Financial Advisor in Board
of Management
Successfully improved Hybrid drugs for solubility
Paclitaxel
Tadalafil
Rapamycin
Bexarotene
verdenafil
5-aminosalicylic
acid
Aspirin
Celecoxib
Docetaxel
Combretastatin
Ibuprofen
Epothione A
Prednisone
Quinine
Itraconazole
Azathioprine
Artemisinin
Cyclosporin
Nimesulide
Rapamycin
Tadalafil
Sildenafil
Aripiprazole
Camptothecin
Paliperidone
Statin
Megastrol
Carbenicillin
verdenafil
5-aminosalicylic
acid
Ofloxacin
Budesonide
Tamoxifen
Finofibrate
Clopidogrel
Valsartan
Other Products ready to market
with cutting edge technology
MARKET OVERVIEW
 Probiotic-----------------------$100M
 UTI -----------------------------$371M
 For joints health-------------$9B
 CurcuTea--------------------- $6.5 billion year 2011
 For Alzheimer's------------- $1.2 billion last year
 Sports Stamina Drink----- $2 billion
 GERD (Acid Reflux)------$11.7B
Diagnostic Test Kits ( Export Only)
 HIV1/2
 HCV
 HepB
 T.B
 Malaria
 Dengue
 Chikungunya
 PSA
 PHASE-1 : Scale cGMP Manufacturing for all
product segments
 PHASE-2 : Animal efficacy: Drug Interactions for
Mewtaxel and marketing of other ready products.
 PHASE-3 : IND and Phase1 clinical
trials.Continue improving the sale of our products
and profit stratigy
Next round of management
discussion
THANK YOU ALL